Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have received a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.80.

AQST has been the subject of several research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday. Finally, Leerink Partners increased their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the second quarter valued at $27,000. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $28,000. SG Americas Securities LLC bought a new stake in Aquestive Therapeutics during the 1st quarter valued at approximately $54,000. The Manufacturers Life Insurance Company bought a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $76,000. Finally, Financial Advocates Investment Management increased its stake in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Up 0.2 %

Shares of AQST opened at $5.08 on Friday. The stock has a 50 day simple moving average of $4.92 and a two-hundred day simple moving average of $3.84. Aquestive Therapeutics has a 1 year low of $1.55 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the company posted ($0.03) earnings per share. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.48 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.